A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
NCT ID: NCT05536440
Last Updated: 2025-03-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
35 participants
INTERVENTIONAL
2022-10-17
2024-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
NCT01897142
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
NCT05434091
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
NCT03217604
First in Human Study for PF-06667272
NCT03126149
A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People
NCT05411588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 active
Dose A
PF-07261271
IV or SC
Cohort 1 placebo
Dose A
Placebo
IV or SC
Cohort 2 active
Dose B
PF-07261271
IV or SC
Cohort 2 placebo
Dose B
Placebo
IV or SC
Cohort 3 active
Dose C
PF-07261271
IV or SC
Cohort 3 placebo
Dose C
Placebo
IV or SC
Cohort 4 active
Dose D
PF-07261271
IV or SC
Cohort 4 placebo
Dose D
Placebo
IV or SC
Cohort 5 active
Dose E
PF-07261271
IV or SC
Cohort 5 placebo
Dose E
Placebo
IV or SC
Cohort 6 active
Dose F
PF-07261271
IV or SC
Cohort 6 placebo
Dose F
Placebo
IV or SC
Cohort 7 active
Dose G
PF-07261271
IV or SC
Cohort 7 placebo
Dose G
Placebo
IV or SC
Cohort 8 active
Dose H
PF-07261271
IV or SC
Cohort 8 placebo
Dose H
Placebo
IV or SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07261271
IV or SC
Placebo
IV or SC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).
Exclusion Criteria
* History of HIV infection, hepatitis B, or hepatitis C
* BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
* Clinically relevant ECG abnormalities
* Previous study drug administration within 30 days or 5 half-lives of first planned dose
* History of drug/alcohol abuse or \>20 cigarettes/day
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orange County Research Center
Lake Forest, California, United States
Orange County Research Center
Tustin, California, United States
Clinilabs
Eatontown, New Jersey, United States
ICON
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C4631001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.